Volume 10, Number 4—April 2004
Research
Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
Emily L.C. Tan*, Eng Eong Ooi†, Chin-Yo Lin*, Hwee Cheng Tan†, Ai Ee Ling‡, Bing Lim*, and Lawrence W. Stanton*
Table 2
Examples of inhibitory concentrations of antiviral drugs against selected virusesa
| Compound | IC50 | Virus |
|---|---|---|
| Foscavir |
50–800 μM |
Cytomegalovirus |
| 5–443 μM |
Herpes simplex mutants |
|
| Acyclovir |
0.01–13.5 μg/ml |
Herpes smplex virus and varicella-zoster virus |
| Cymevene |
0.02–3.48 μg/mL |
Laboratory strains or clinical isolates of cytomegalovirus |
| Ribavirin |
1–25 μg/mL |
Influenza |
| 25–100 μg/mL |
HIV and other retroviruses |
|
| 3.2–50 μg/ml (MIC) |
Herpes and poxviruses suppression |
|
| Lamivudine |
0.0006–0.034 μg/mL |
HIV |
| Zidovudine |
0.003–0.013 μg/mL |
HIV |
| Fortovase |
1–30 nM |
HIV |
| Viracept |
7–196 nM (EC95) |
HIV |
| Crixivan |
25–100 nM |
HIV |
| Relenza |
0.005–16 μM |
Influenza virus |
| Tamiflu |
0.0008 μM–>35 μM |
Influenza virus |
| Amantadine | 0.1–25 (ED50) | Influenza virus |
aIC50, 50% inhibitory concentration; EC95, 95% effective concentration; ED50, 50% effective dose.
Page created: February 09, 2011
Page updated: February 09, 2011
Page reviewed: February 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.